跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,817 条关于
“NT-0150”
全部
1,817
临床试验
1,040
药物
592
机构
3
资讯
182
3个月前
NodThera's NLRP3 Inhibitor Ruvonoflast Shows Promising Anti-Inflammatory Effects in Cardiovascular Risk Patients
9天前
Rezera's Oral NLRP3 Inhibitor Ruvonoflast Hits Primary Inflammation Endpoint in Phase 2 RESOLVE-1, Phase 3 PAD Trial Planned for 2027
2年前
Revolution Medicines' RMC-6236: A Novel Pan-RAS(ON) Inhibitor Shows Promise in 'Undruggable' Tumors
2年前
FDA Extends Review of Neurotech's NT-501 for Macular Telangiectasia Type 2
去年
FDA Extends Review Timeline for Neurotech's NT-501 MacTel Treatment
去年
NT-501 Shows Promise in MacTel Treatment: Pooled Data Reveals Functional and Structural Benefits
2年前
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for Advanced Pancreatic Cancer Treatment
去年
NT-501 Encapsulated Cell Therapy Shows Promise in Glaucoma Neuroprotection
去年
NT-301 Nasal Spray Shows Promising Phase 1 Results for Parkinson's Disease OFF Episodes
去年
Primo Biotechnology Raises NT$220M Series A to Advance Radioligand Theranostics Platform
第 1 页,共 19 页
上一页
下一页